Inici › Mieloma múltiple › Wisconsin › Milwaukee
Assaigs clínics de Mieloma múltiple a Milwaukee, WI
21 estudis de Mieloma múltiple busquen participants en centres de Milwaukee i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutantFase 3
- Research Site, Milwaukee
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
ReclutantFase 1/2
- Medical College of Wisconsin, Milwaukee
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 3
- Medical College Of Wisconsin, Milwaukee
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ReclutantFase 4
- Froedtert Memorial, Milwaukee
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1/2
- The Medical College of Wisconsin, Milwaukee
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ReclutantFase 2
- Aurora Cancer Care Milwaukee, Milwaukee
- Aurora St. Luke's Medical Center, Milwaukee
- Aurora Sinai Medical Center, Milwaukee
- i 4 més
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutantFase 3
- Medical College of Wisconsin, Milwaukee
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutantFase 3
- Medical College of Wisconsin, Milwaukee
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
ReclutantFase 1/2
- Research Site, Milwaukee
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutantFase 3
- Aurora Cancer Care-Milwaukee, Milwaukee
- Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee, Milwaukee
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus, Milwaukee
- i 13 més
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ReclutantFase 1/2
- Research Site, Milwaukee
Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma
ReclutantFase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ReclutantFase 2
- MCW-Clinical Cancer Center at Froedtert Hospital Campus, Milwaukee
Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
Reclutant
- Medical College of Wisconsin, Milwaukee
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutantFase 3
- Froedtert Memorial Lutheran Hospital, Milwaukee
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
ReclutantFase 2
- Medical College of Wisconsin, Milwaukee
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ReclutantFase 1
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency
ReclutantFase 2
- Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma
ReclutantFase 1
- Froedtert & the Medical College of Wisconsin, Milwaukee
Long-term Follow-up Study of Patients Receiving CAR-T Cells
ReclutantEstudi observacional
- Froedtert Hospital & Medical College of Wisconsin, Milwaukee
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
ReclutantFase 1
- Froedtert and the Medical College of Wisconsin, Milwaukee
Assaigs de Mieloma múltiple en altres ciutats
- New York City, NY60 estudis
- Boston, MA42 estudis
- Atlanta, GA41 estudis
- Houston, TX38 estudis
- Durham, NC37 estudis
- Nashville, TN32 estudis
- Denver, CO27 estudis
- Rochester, MN24 estudis
- St. Louis, MO24 estudis
- Columbus, OH24 estudis
- Baldwin Park, CA23 estudis
- Chicago, IL22 estudis
Altres estudis a Milwaukee
- Càncer de mama23 estudis
- Càncer de pulmó de cèl·lules no petites22 estudis
- Càncer (tots els tipus)22 estudis
- Càncer de pulmó21 estudis
- Càncer de pròstata20 estudis
- Limfoma fol·licular19 estudis
- Càncer de pàncrees18 estudis
- Limfoma no Hodgkin18 estudis
- Càncer d'ovari17 estudis
- Leucèmia mieloide aguda17 estudis
- Limfoma de Burkitt16 estudis
- Insuficiència cardíaca16 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.